|
MSH3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.50229886495413E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.08419997611054E-09 |
| Normal-vs-Stage2 |
2.809600E-04 |
| Normal-vs-Stage3 |
6.62889998448435E-09 |
| Normal-vs-Stage4 |
1.49169999996701E-06 |
| Stage1-vs-Stage2 |
4.875200E-01 |
| Stage1-vs-Stage3 |
8.184500E-02 |
| Stage1-vs-Stage4 |
6.456200E-01 |
| Stage2-vs-Stage3 |
5.666500E-02 |
| Stage2-vs-Stage4 |
3.340800E-01 |
| Stage3-vs-Stage4 |
3.964200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.09879940888436E-11 |
| Normal-vs-AfricanAmerican |
4.059000E-03 |
| Normal-vs-Asian |
9.78080000000325E-05 |
| Caucasian-vs-AfricanAmerican |
2.892600E-01 |
| Caucasian-vs-Asian |
3.272600E-01 |
| AfricanAmerican-vs-Asian |
7.680000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.4639999757502E-09 |
| Normal-vs-Female |
8.51509973642806E-10 |
| Male-vs-Female |
3.407000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.83120000461091E-08 |
| Normal-vs-Age(41-60Yrs) |
4.83669992945579E-10 |
| Normal-vs-Age(61-80Yrs) |
1.1761999996196E-07 |
| Normal-vs-Age(81-100Yrs) |
2.743600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.868600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.311800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.506600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.851800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.763200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.527600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.358000E-02 |
| Classical-VS-Follicular |
4.116200E-01 |
| Classical-VS-Other |
3.127600E-01 |
| Classical-VS-Normal |
1.70070000304889E-08 |
| Tall-VS-Follicular |
1.678040E-01 |
| Tall-VS-Other |
9.205800E-01 |
| Tall-VS-Normal |
6.06579999562484E-08 |
| Follicular-VS-Other |
4.764800E-01 |
| Follicular-VS-Normal |
3.43389999990507E-07 |
| Other-VS-Normal |
6.737100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.47829997926885E-09 |
| Normal-vs-N1 |
8.33869999716796E-08 |
| N0-vs-N1 |
3.196800E-01 |
|
|
